Recent developments highlight Cognition Therapeutics' narrowing Q3 losses, FDA alignment for pivotal Phase 3 trials of Zervimesine in dementia with Lewy bodies, and receipt of a Nasdaq deficiency letter due to stock price compliance issues.

• Cognition reported a Q3 2026 net loss of approximately $4 million, reflecting a narrowing loss compared to prior periods [N1].
• The company has aligned with the FDA on a pivotal Phase 3 trial for Zervimesine in dementia with Lewy bodies, with plans to initiate the study in mid-2027 [N5][N6].
• Cognition received a Nasdaq deficiency letter on November 3, 2026, due to its common stock closing below $1.00 per share for 30 consecutive trading days, with a compliance deadline of May 3, 2027 [N4].
• The company is considering options to regain Nasdaq compliance, including a potential reverse stock split [N4].
• Q3 2026 earnings call highlighted ongoing clinical development progress and financial results [N2][N3].

The company has demonstrated clinical progress with Zervimesine, including promising Phase 2 results and FDA alignment for Phase 3 trials in dementia with Lewy bodies. Narrowing net losses and strong liquidity provide operational runway to advance clinical programs. Successful execution of the Phase 3 trial could validate the novel sigma-2 receptor targeting approach, potentially addressing significant unmet needs in neurodegenerative diseases. Regulatory alignment and ongoing clinical development milestones support the company's strategic positioning in this therapeutic area.

Cognition Therapeutics faces risks typical of clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company reported ongoing net losses and must manage capital requirements to sustain operations. The Nasdaq deficiency letter due to stock price below $1.00 per share introduces risk of delisting, which could impact liquidity and capital access. Competition from other therapies and the novel nature of the sigma-2 receptor targeting approach add to execution risks. Failure to regain Nasdaq compliance or secure additional financing could materially affect the company's operations.

Cognition Therapeutics' moat lies in its novel therapeutic approach targeting the sigma-2 receptor complex for neurodegenerative diseases, an area with significant unmet medical need. The company's lead candidate, Zervimesine, has progressed through Phase 2 studies with promising results and has secured FDA alignment for pivotal Phase 3 trials. This regulatory alignment and clinical progress provide a competitive advantage in a challenging therapeutic area. However, as a clinical-stage biotech, the moat is contingent on successful clinical development and eventual regulatory approval, with competition from other therapies in the neurodegenerative disease space.

• Nasdaq Listing Compliance Risk: The company received a Nasdaq deficiency letter for its stock price falling below $1.00 per share for 30 consecutive trading days, with a deadline to regain compliance by May 3, 2027. Failure to comply could result in delisting, negatively impacting liquidity and capital access.
• Clinical and Regulatory Risk: As a clinical-stage biotech, Cognition faces risks related to the success, timing, and regulatory approval of its clinical trials, particularly the pivotal Phase 3 trial for Zervimesine.
• Capital and Liquidity Risk: The company reports net losses and depends on raising additional capital to fund ongoing operations and clinical development. Insufficient financing could impair its ability to continue operations.
• Market and Competitive Risk: Competition from other therapies for neurodegenerative diseases and the novel nature of the sigma-2 receptor targeting approach may affect market acceptance and commercial viability.

• Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, notably dementia with Lewy bodies (DLB) and Alzheimer's disease.
• The company's lead product candidate is Zervimesine (CT1812), targeting the sigma-2 receptor complex to treat age-related degenerative diseases.
• Cognition has aligned with the FDA on a pivotal Phase 3 trial for Zervimesine in dementia with Lewy bodies, with plans for the study to start in mid-2027.
• The company reported a net loss of $4.145 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.04 per share.
• As of September 30, 2026, Cognition held $30.758 million in cash and cash equivalents, with current assets of $34.239 million and current liabilities of $5.128 million, resulting in a current ratio of 6.68 and a cash ratio of 6, indicating strong liquidity.
• Cognition received a Nasdaq deficiency letter on November 3, 2026, due to its common stock closing below $1.00 per share for 30 consecutive trading days, with a compliance deadline of May 3, 2027.
• The company is considering options to regain Nasdaq compliance, including a potential reverse stock split.
• Cognition's Q3 2026 loss narrowed compared to prior periods, reflecting ongoing cost management efforts.
• The company has ongoing clinical trials and development activities, with risks including regulatory approval, clinical trial success, capital raising, and market competition.
• Cognition Therapeutics is listed on the Nasdaq Stock Market under the ticker CGTX.
• The company has disclosed risk factors related to its clinical-stage status, regulatory uncertainties, capital requirements, and Nasdaq listing compliance risks in its SEC filings.